The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-09-20

AUTHORS

Emanuela Palmerini, Marco Colangeli, Cristina Nanni, Stefano Fanti, Emanuela Marchesi, Anna Paioli, Piero Picci, Silvia Cambioli, Davide Donati, Luca Cevolani, Massimiliano De Paolis, Marco Gambarotti, Stefano Ferrari

ABSTRACT

PurposeThe histological response to neoadjuvant chemotherapy is an important prognostic factor in patients with osteosarcoma (OS) and Ewing sarcoma (EWS). The aim of this study was to assess baseline primary tumour FDG uptake on PET/CT, and serum values of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH), to establish whether these factors are correlated with tumour necrosis and prognosis.MethodsPatients treated between 2009 and 2014 for localized EWS and OS, who underwent FDG PET/CT as part of their staging work-up, were included. The relationships between primary tumour SUVmax at baseline (SUV1), SUVmax after induction chemotherapy (SUV2), metabolic response calculated as [(SUV1 − SUV2)/SUV1)] × 100, LDH and ALP and tumour response/survival were analysed. A good response (GR) was defined as tumour necrosis >90 % in patients with OS, and grade II-III Picci necrosis (persitence of microscopic foci only or no viable tumor) in patients with Ewing sarcoma.ResultsThe study included 77 patients, 45 with EWS and 32 with OS. A good histological response was achieved in 53 % of EWS patients, and 41 % of OS patients. The 3-year event-free survival (EFS) was 57 % in EWS patients and 48 % OS patients. The median SUV1 was 5.6 (range 0 – 17) in EWS patients and 7.9 (range 0 – 24) in OS patients (p = 0.006). In EWS patients the GR rate was 30 % in those with a high SUV1 (≥6) and 72 % in those with a lower SUV1 (p = 0.0004), and in OS patients the GR rate was 29 % in those with SUV1 ≥6 and 64 % in those with a lower SUV1 (p = 0.05). In the univariate analysis the 3-year EFS was significantly better in patients with a low ALP level (59 %) than in those with a high ALP level (22 %, p = 0.02) and in patients with a low LDH level (62 %) than in those with a high LDH level (37 %, p = 0.004). In EWS patients the 3-year EFS was 37 % in those with a high SUV1 and 75 % in those with a low SUV1 (p = 0.004), and in OS patients the 3-year EFS was 32 % in those with a high SUV1 and 66 % in those with a low SUV1 (p = 0.1). Histology, age and gender were not associated with survival. In the multivariate analysis, SUV1 was the only independent pretreatment prognostic factor to retain statistical significance (p = 0.017). SUV2 was assessed in 25 EWS patients: the median SUV2 was 1.9 (range 1 – 8). The GR rate was 20 % in patients with a high SUV2, and 67 % in those with a low SUV2 (p = 0.02). A good metabolic response (SUV reduction of ≥55 %) was associated with a 3-year EFS of 80 % and a poor metabolic response with a 3-year EFS of 20 % (p = 0.05). In the OS patients the median SUV2 was 2.7 (range 0 – 4.5). Neither SUV2 nor the metabolic response was associated with outcome in OS patients.ConclusionFDG PET/CT is a useful and noninvasive tool for identifying patients who are more likely to be resistant to chemotherapy. If this finding is confirmed in a larger series, SUV1, SUV2 and metabolic response could be proposed as factors for stratifying EWS patients to identify those with high-grade localized bone EWS who would benefit from risk-adapted induction chemotherapy. More... »

PAGES

215-223

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00259-016-3509-z

DOI

http://dx.doi.org/10.1007/s00259-016-3509-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1018885026

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27645694


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemoradiotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorodeoxyglucose F18", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Italy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoadjuvant Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron Emission Tomography Computed Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prevalence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiopharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sarcoma, Ewing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palmerini", 
        "givenName": "Emanuela", 
        "id": "sg:person.01210215667.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210215667.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Colangeli", 
        "givenName": "Marco", 
        "id": "sg:person.01003041354.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003041354.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine, Sant\u2019 Orsola Hospital, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.412311.4", 
          "name": [
            "Nuclear Medicine, Sant\u2019 Orsola Hospital, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nanni", 
        "givenName": "Cristina", 
        "id": "sg:person.01275354033.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275354033.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine, Sant\u2019 Orsola Hospital, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.412311.4", 
          "name": [
            "Nuclear Medicine, Sant\u2019 Orsola Hospital, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fanti", 
        "givenName": "Stefano", 
        "id": "sg:person.0715016706.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715016706.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marchesi", 
        "givenName": "Emanuela", 
        "id": "sg:person.0720354404.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720354404.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paioli", 
        "givenName": "Anna", 
        "id": "sg:person.01235471460.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235471460.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Laboratory, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Research Laboratory, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Picci", 
        "givenName": "Piero", 
        "id": "sg:person.0753274552.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753274552.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuclear Medicine, Sant\u2019 Orsola Hospital, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.412311.4", 
          "name": [
            "Nuclear Medicine, Sant\u2019 Orsola Hospital, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cambioli", 
        "givenName": "Silvia", 
        "id": "sg:person.01057244143.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057244143.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Donati", 
        "givenName": "Davide", 
        "id": "sg:person.01202643430.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202643430.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cevolani", 
        "givenName": "Luca", 
        "id": "sg:person.01007135564.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007135564.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Paolis", 
        "givenName": "Massimiliano", 
        "id": "sg:person.0705203110.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705203110.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radiology, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Surgical Pathology, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
            "Radiology, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gambarotti", 
        "givenName": "Marco", 
        "id": "sg:person.01334463454.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334463454.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ferrari", 
        "givenName": "Stefano", 
        "id": "sg:person.013005321532.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013005321532.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10549-014-2924-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049588764", 
          "https://doi.org/10.1007/s10549-014-2924-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7819-12-26", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032219566", 
          "https://doi.org/10.1186/1477-7819-12-26"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002590000340", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019676038", 
          "https://doi.org/10.1007/s002590000340"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12094-015-1351-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009995151", 
          "https://doi.org/10.1007/s12094-015-1351-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-013-2344-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010594474", 
          "https://doi.org/10.1007/s00259-013-2344-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-015-3200-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013429857", 
          "https://doi.org/10.1007/s00259-015-3200-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-09-20", 
    "datePublishedReg": "2016-09-20", 
    "description": "PurposeThe histological response to neoadjuvant chemotherapy is an important prognostic factor in patients with osteosarcoma (OS) and Ewing sarcoma (EWS). The aim of this study was to assess baseline primary tumour FDG uptake on PET/CT, and serum values of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH), to establish whether these factors are correlated with tumour necrosis and prognosis.MethodsPatients treated between 2009 and 2014 for localized EWS and OS, who underwent FDG PET/CT as part of their staging work-up, were included. The relationships between primary tumour SUVmax at baseline (SUV1), SUVmax after induction chemotherapy (SUV2), metabolic response calculated as [(SUV1\u2009\u2212\u2009SUV2)/SUV1)]\u2009\u00d7\u2009100, LDH and ALP and tumour response/survival were analysed. A good response (GR) was defined as tumour necrosis >90\u00a0% in patients with OS, and grade II-III Picci necrosis (persitence of microscopic foci only or no viable tumor) in patients with Ewing sarcoma.ResultsThe study included 77 patients, 45 with EWS and 32 with OS. A good histological response was achieved in 53\u00a0% of EWS patients, and 41\u00a0% of OS patients. The 3-year event-free survival (EFS) was 57\u00a0% in EWS patients and 48\u00a0% OS patients. The median SUV1 was 5.6 (range 0\u2009\u2013\u200917) in EWS patients and 7.9 (range 0\u2009\u2013\u200924) in OS patients (p\u2009=\u20090.006). In EWS patients the GR rate was 30\u00a0% in those with a high SUV1 (\u22656) and 72\u00a0% in those with a lower SUV1 (p\u2009=\u20090.0004), and in OS patients the GR rate was 29\u00a0% in those with SUV1 \u22656 and 64\u00a0% in those with a lower SUV1 (p\u2009=\u20090.05). In the univariate analysis the 3-year EFS was significantly better in patients with a low ALP level (59\u00a0%) than in those with a high ALP level (22\u00a0%, p\u2009=\u20090.02) and in patients with a low LDH level (62\u00a0%) than in those with a high LDH level (37\u00a0%, p\u2009=\u20090.004). In EWS patients the 3-year EFS was 37\u00a0% in those with a high SUV1 and 75\u00a0% in those with a low SUV1 (p\u2009=\u20090.004), and in OS patients the 3-year EFS was 32\u00a0% in those with a high SUV1 and 66\u00a0% in those with a low SUV1 (p\u2009=\u20090.1). Histology, age and gender were not associated with survival. In the multivariate analysis, SUV1 was the only independent pretreatment prognostic factor to retain statistical significance (p\u2009=\u20090.017). SUV2 was assessed in 25 EWS patients: the median SUV2 was 1.9 (range 1\u2009\u2013\u20098). The GR rate was 20\u00a0% in patients with a high SUV2, and 67\u00a0% in those with a low SUV2 (p\u2009=\u20090.02). A good metabolic response (SUV reduction of \u226555\u00a0%) was associated with a 3-year EFS of 80\u00a0% and a poor metabolic response with a 3-year EFS of 20\u00a0% (p\u2009=\u20090.05). In the OS patients the median SUV2 was 2.7 (range 0\u2009\u2013\u20094.5). Neither SUV2 nor the metabolic response was associated with outcome in OS patients.ConclusionFDG PET/CT is a useful and noninvasive tool for identifying patients who are more likely to be resistant to chemotherapy. If this finding is confirmed in a larger series, SUV1, SUV2 and metabolic response could be proposed as factors for stratifying EWS patients to identify those with high-grade localized bone EWS who would benefit from risk-adapted induction chemotherapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00259-016-3509-z", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297401", 
        "issn": [
          "1619-7070", 
          "1619-7089"
        ], 
        "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "keywords": [
      "event-free survival", 
      "PET/CT", 
      "FDG PET/CT", 
      "OS patients", 
      "Ewing's sarcoma", 
      "EWS patients", 
      "neoadjuvant chemotherapy", 
      "induction chemotherapy", 
      "prognostic factors", 
      "LDH levels", 
      "metabolic response", 
      "tumor necrosis", 
      "histological response", 
      "ALP levels", 
      "ConclusionFDG PET/CT", 
      "primary tumor FDG uptake", 
      "good histological response", 
      "poor metabolic response", 
      "bone Ewing's sarcoma", 
      "primary tumor SUVmax", 
      "high LDH levels", 
      "pretreatment prognostic factors", 
      "important prognostic factor", 
      "tumor FDG uptake", 
      "response/survival", 
      "alkaline phosphatase", 
      "good metabolic response", 
      "low ALP levels", 
      "good response", 
      "lower LDH levels", 
      "higher ALP levels", 
      "tumor SUVmax", 
      "bone sarcomas", 
      "FDG uptake", 
      "grade II", 
      "univariate analysis", 
      "ResultsThe study", 
      "serum values", 
      "chemotherapy", 
      "patients", 
      "SUV1", 
      "large series", 
      "multivariate analysis", 
      "osteosarcoma", 
      "SUV2", 
      "noninvasive tool", 
      "sarcoma", 
      "necrosis", 
      "CT", 
      "statistical significance", 
      "SUVmax", 
      "survival", 
      "response", 
      "MethodsPatients", 
      "prognosis", 
      "factors", 
      "levels", 
      "histology", 
      "baseline", 
      "age", 
      "outcomes", 
      "rate", 
      "study", 
      "gender", 
      "aim", 
      "findings", 
      "LDH", 
      "uptake", 
      "phosphatase", 
      "dehydrogenase", 
      "GR rate", 
      "significance", 
      "role", 
      "analysis", 
      "relationship", 
      "series", 
      "part", 
      "tool", 
      "values"
    ], 
    "name": "The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas", 
    "pagination": "215-223", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1018885026"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00259-016-3509-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27645694"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00259-016-3509-z", 
      "https://app.dimensions.ai/details/publication/pub.1018885026"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_718.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00259-016-3509-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-016-3509-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-016-3509-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-016-3509-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-016-3509-z'


 

This table displays all metadata directly associated to this object as RDF triples.

350 TRIPLES      21 PREDICATES      133 URIs      118 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00259-016-3509-z schema:about N03af4301cee548e3b0ad665c69a92fd7
2 N058cf2d724ac432c9858b32784d22e0d
3 N07a1e91b7c8048bfacfcd86ef54048fb
4 N125e60aea8414ebd80bb4e1fafd6a2bc
5 N1c96935271d34a1abb5e718f7379f85c
6 N49646c6b0fd24ff480878338a97fa39d
7 N5afec3a5d56744fa882f23c6b7536f52
8 N6a4a234cae17488d9bb28506b083e461
9 N7ebf5fe4c406480987cbaf2713f7f0de
10 N94cf6864d4434ea2ae8a27073a40fc01
11 N95da9e98950b4605a29bf560669f1daa
12 Na4f85fd2ba5945fca91a2775dbdc9a84
13 Naadf25d359b144ee85b7d71d56588461
14 Nbbe8ab4a65124bc5a9417a17f412aff8
15 Nbd0e78eb006948de876ac98e80923e10
16 Nbe7418087a434e2c972c7b663d039586
17 Nc7c9b73093be42e7a4af176f4a0efcba
18 Ncaeeade2e93a4f9192f109179f502673
19 Ndc83838989204d6fae0d7a71aabccf96
20 Nf7101e8e8aa7447fb1c8a787c75945aa
21 Nfae50a0764a14833a271c063d95688dc
22 Nfb3805bc767c4a2fb90fd7fbd79e6c6a
23 anzsrc-for:11
24 anzsrc-for:1103
25 anzsrc-for:1112
26 schema:author Nfcd2dc97a1dd445e840615375bff1249
27 schema:citation sg:pub.10.1007/s00259-013-2344-8
28 sg:pub.10.1007/s00259-015-3200-9
29 sg:pub.10.1007/s002590000340
30 sg:pub.10.1007/s10549-014-2924-8
31 sg:pub.10.1007/s12094-015-1351-6
32 sg:pub.10.1186/1477-7819-12-26
33 schema:datePublished 2016-09-20
34 schema:datePublishedReg 2016-09-20
35 schema:description PurposeThe histological response to neoadjuvant chemotherapy is an important prognostic factor in patients with osteosarcoma (OS) and Ewing sarcoma (EWS). The aim of this study was to assess baseline primary tumour FDG uptake on PET/CT, and serum values of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH), to establish whether these factors are correlated with tumour necrosis and prognosis.MethodsPatients treated between 2009 and 2014 for localized EWS and OS, who underwent FDG PET/CT as part of their staging work-up, were included. The relationships between primary tumour SUVmax at baseline (SUV1), SUVmax after induction chemotherapy (SUV2), metabolic response calculated as [(SUV1 − SUV2)/SUV1)] × 100, LDH and ALP and tumour response/survival were analysed. A good response (GR) was defined as tumour necrosis >90 % in patients with OS, and grade II-III Picci necrosis (persitence of microscopic foci only or no viable tumor) in patients with Ewing sarcoma.ResultsThe study included 77 patients, 45 with EWS and 32 with OS. A good histological response was achieved in 53 % of EWS patients, and 41 % of OS patients. The 3-year event-free survival (EFS) was 57 % in EWS patients and 48 % OS patients. The median SUV1 was 5.6 (range 0 – 17) in EWS patients and 7.9 (range 0 – 24) in OS patients (p = 0.006). In EWS patients the GR rate was 30 % in those with a high SUV1 (≥6) and 72 % in those with a lower SUV1 (p = 0.0004), and in OS patients the GR rate was 29 % in those with SUV1 ≥6 and 64 % in those with a lower SUV1 (p = 0.05). In the univariate analysis the 3-year EFS was significantly better in patients with a low ALP level (59 %) than in those with a high ALP level (22 %, p = 0.02) and in patients with a low LDH level (62 %) than in those with a high LDH level (37 %, p = 0.004). In EWS patients the 3-year EFS was 37 % in those with a high SUV1 and 75 % in those with a low SUV1 (p = 0.004), and in OS patients the 3-year EFS was 32 % in those with a high SUV1 and 66 % in those with a low SUV1 (p = 0.1). Histology, age and gender were not associated with survival. In the multivariate analysis, SUV1 was the only independent pretreatment prognostic factor to retain statistical significance (p = 0.017). SUV2 was assessed in 25 EWS patients: the median SUV2 was 1.9 (range 1 – 8). The GR rate was 20 % in patients with a high SUV2, and 67 % in those with a low SUV2 (p = 0.02). A good metabolic response (SUV reduction of ≥55 %) was associated with a 3-year EFS of 80 % and a poor metabolic response with a 3-year EFS of 20 % (p = 0.05). In the OS patients the median SUV2 was 2.7 (range 0 – 4.5). Neither SUV2 nor the metabolic response was associated with outcome in OS patients.ConclusionFDG PET/CT is a useful and noninvasive tool for identifying patients who are more likely to be resistant to chemotherapy. If this finding is confirmed in a larger series, SUV1, SUV2 and metabolic response could be proposed as factors for stratifying EWS patients to identify those with high-grade localized bone EWS who would benefit from risk-adapted induction chemotherapy.
36 schema:genre article
37 schema:isAccessibleForFree true
38 schema:isPartOf Nc1e333d9579f44ea8398b291f34451ec
39 Ndae90463a25247b097fe0a218c98a921
40 sg:journal.1297401
41 schema:keywords ALP levels
42 CT
43 ConclusionFDG PET/CT
44 EWS patients
45 Ewing's sarcoma
46 FDG PET/CT
47 FDG uptake
48 GR rate
49 LDH
50 LDH levels
51 MethodsPatients
52 OS patients
53 PET/CT
54 ResultsThe study
55 SUV1
56 SUV2
57 SUVmax
58 age
59 aim
60 alkaline phosphatase
61 analysis
62 baseline
63 bone Ewing's sarcoma
64 bone sarcomas
65 chemotherapy
66 dehydrogenase
67 event-free survival
68 factors
69 findings
70 gender
71 good histological response
72 good metabolic response
73 good response
74 grade II
75 high LDH levels
76 higher ALP levels
77 histological response
78 histology
79 important prognostic factor
80 induction chemotherapy
81 large series
82 levels
83 low ALP levels
84 lower LDH levels
85 metabolic response
86 multivariate analysis
87 necrosis
88 neoadjuvant chemotherapy
89 noninvasive tool
90 osteosarcoma
91 outcomes
92 part
93 patients
94 phosphatase
95 poor metabolic response
96 pretreatment prognostic factors
97 primary tumor FDG uptake
98 primary tumor SUVmax
99 prognosis
100 prognostic factors
101 rate
102 relationship
103 response
104 response/survival
105 role
106 sarcoma
107 series
108 serum values
109 significance
110 statistical significance
111 study
112 survival
113 tool
114 tumor FDG uptake
115 tumor SUVmax
116 tumor necrosis
117 univariate analysis
118 uptake
119 values
120 schema:name The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas
121 schema:pagination 215-223
122 schema:productId N52342cbb6b30437f934cad6cd2901339
123 Na2c7f3f9cba44ea38c92ab1f4ff24a97
124 Nd9735aa7f7b64baf98f2762e46ca8f65
125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018885026
126 https://doi.org/10.1007/s00259-016-3509-z
127 schema:sdDatePublished 2022-09-02T15:59
128 schema:sdLicense https://scigraph.springernature.com/explorer/license/
129 schema:sdPublisher N4b892fbf41f84e9b9307a4d59c5accea
130 schema:url https://doi.org/10.1007/s00259-016-3509-z
131 sgo:license sg:explorer/license/
132 sgo:sdDataset articles
133 rdf:type schema:ScholarlyArticle
134 N02b46a7401e542eb8fc88d4a95544f2e rdf:first sg:person.0705203110.24
135 rdf:rest N5e62d73b9b2d4c06a273a20e746a814e
136 N03af4301cee548e3b0ad665c69a92fd7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Chemoradiotherapy, Adjuvant
138 rdf:type schema:DefinedTerm
139 N058cf2d724ac432c9858b32784d22e0d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Prevalence
141 rdf:type schema:DefinedTerm
142 N07a1e91b7c8048bfacfcd86ef54048fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Adolescent
144 rdf:type schema:DefinedTerm
145 N07f4fcba7bf3440da21ad3b5ecf4eb9e rdf:first sg:person.01057244143.41
146 rdf:rest N3b5b8c567c0949a58b2d1e5986015430
147 N125e60aea8414ebd80bb4e1fafd6a2bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Bone Neoplasms
149 rdf:type schema:DefinedTerm
150 N1c96935271d34a1abb5e718f7379f85c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Sarcoma, Ewing
152 rdf:type schema:DefinedTerm
153 N2fb69c8d71c74fe793ecabb36b52acbb rdf:first sg:person.0715016706.32
154 rdf:rest N63389965b9c1435080aef55a0743d89a
155 N3b5b8c567c0949a58b2d1e5986015430 rdf:first sg:person.01202643430.41
156 rdf:rest Nebb982709860450c863d60087867a77a
157 N49646c6b0fd24ff480878338a97fa39d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Young Adult
159 rdf:type schema:DefinedTerm
160 N4b892fbf41f84e9b9307a4d59c5accea schema:name Springer Nature - SN SciGraph project
161 rdf:type schema:Organization
162 N52342cbb6b30437f934cad6cd2901339 schema:name pubmed_id
163 schema:value 27645694
164 rdf:type schema:PropertyValue
165 N5afec3a5d56744fa882f23c6b7536f52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Male
167 rdf:type schema:DefinedTerm
168 N5e62d73b9b2d4c06a273a20e746a814e rdf:first sg:person.01334463454.00
169 rdf:rest Na41d4292d45846198183d4734b663d57
170 N63389965b9c1435080aef55a0743d89a rdf:first sg:person.0720354404.13
171 rdf:rest N9f723e94895a482c812d3d9603eabb01
172 N6a4a234cae17488d9bb28506b083e461 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Humans
174 rdf:type schema:DefinedTerm
175 N70328974890849dbb71c2a8474b07011 rdf:first sg:person.01003041354.87
176 rdf:rest Nf4a22162b9b0472aa82a1e7ae6b2bd4c
177 N7cb90b3579ce497786678c553ecf92c7 rdf:first sg:person.0753274552.44
178 rdf:rest N07f4fcba7bf3440da21ad3b5ecf4eb9e
179 N7ebf5fe4c406480987cbaf2713f7f0de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Survival Rate
181 rdf:type schema:DefinedTerm
182 N94cf6864d4434ea2ae8a27073a40fc01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Radiopharmaceuticals
184 rdf:type schema:DefinedTerm
185 N95da9e98950b4605a29bf560669f1daa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Neoadjuvant Therapy
187 rdf:type schema:DefinedTerm
188 N9f723e94895a482c812d3d9603eabb01 rdf:first sg:person.01235471460.73
189 rdf:rest N7cb90b3579ce497786678c553ecf92c7
190 Na2c7f3f9cba44ea38c92ab1f4ff24a97 schema:name doi
191 schema:value 10.1007/s00259-016-3509-z
192 rdf:type schema:PropertyValue
193 Na41d4292d45846198183d4734b663d57 rdf:first sg:person.013005321532.44
194 rdf:rest rdf:nil
195 Na4f85fd2ba5945fca91a2775dbdc9a84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Prognosis
197 rdf:type schema:DefinedTerm
198 Naadf25d359b144ee85b7d71d56588461 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Adult
200 rdf:type schema:DefinedTerm
201 Nbbe8ab4a65124bc5a9417a17f412aff8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Italy
203 rdf:type schema:DefinedTerm
204 Nbd0e78eb006948de876ac98e80923e10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Child, Preschool
206 rdf:type schema:DefinedTerm
207 Nbe7418087a434e2c972c7b663d039586 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Risk Factors
209 rdf:type schema:DefinedTerm
210 Nc1e333d9579f44ea8398b291f34451ec schema:volumeNumber 44
211 rdf:type schema:PublicationVolume
212 Nc7c9b73093be42e7a4af176f4a0efcba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Treatment Outcome
214 rdf:type schema:DefinedTerm
215 Ncaeeade2e93a4f9192f109179f502673 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name Positron Emission Tomography Computed Tomography
217 rdf:type schema:DefinedTerm
218 Nd9735aa7f7b64baf98f2762e46ca8f65 schema:name dimensions_id
219 schema:value pub.1018885026
220 rdf:type schema:PropertyValue
221 Ndae90463a25247b097fe0a218c98a921 schema:issueNumber 2
222 rdf:type schema:PublicationIssue
223 Ndc83838989204d6fae0d7a71aabccf96 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
224 schema:name Risk Assessment
225 rdf:type schema:DefinedTerm
226 Nebb982709860450c863d60087867a77a rdf:first sg:person.01007135564.48
227 rdf:rest N02b46a7401e542eb8fc88d4a95544f2e
228 Nf4a22162b9b0472aa82a1e7ae6b2bd4c rdf:first sg:person.01275354033.99
229 rdf:rest N2fb69c8d71c74fe793ecabb36b52acbb
230 Nf7101e8e8aa7447fb1c8a787c75945aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
231 schema:name Child
232 rdf:type schema:DefinedTerm
233 Nfae50a0764a14833a271c063d95688dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
234 schema:name Female
235 rdf:type schema:DefinedTerm
236 Nfb3805bc767c4a2fb90fd7fbd79e6c6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
237 schema:name Fluorodeoxyglucose F18
238 rdf:type schema:DefinedTerm
239 Nfcd2dc97a1dd445e840615375bff1249 rdf:first sg:person.01210215667.35
240 rdf:rest N70328974890849dbb71c2a8474b07011
241 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
242 schema:name Medical and Health Sciences
243 rdf:type schema:DefinedTerm
244 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
245 schema:name Clinical Sciences
246 rdf:type schema:DefinedTerm
247 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
248 schema:name Oncology and Carcinogenesis
249 rdf:type schema:DefinedTerm
250 sg:journal.1297401 schema:issn 1619-7070
251 1619-7089
252 schema:name European Journal of Nuclear Medicine and Molecular Imaging
253 schema:publisher Springer Nature
254 rdf:type schema:Periodical
255 sg:person.01003041354.87 schema:affiliation grid-institutes:grid.419038.7
256 schema:familyName Colangeli
257 schema:givenName Marco
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003041354.87
259 rdf:type schema:Person
260 sg:person.01007135564.48 schema:affiliation grid-institutes:grid.419038.7
261 schema:familyName Cevolani
262 schema:givenName Luca
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007135564.48
264 rdf:type schema:Person
265 sg:person.01057244143.41 schema:affiliation grid-institutes:grid.412311.4
266 schema:familyName Cambioli
267 schema:givenName Silvia
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057244143.41
269 rdf:type schema:Person
270 sg:person.01202643430.41 schema:affiliation grid-institutes:grid.419038.7
271 schema:familyName Donati
272 schema:givenName Davide
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01202643430.41
274 rdf:type schema:Person
275 sg:person.01210215667.35 schema:affiliation grid-institutes:grid.419038.7
276 schema:familyName Palmerini
277 schema:givenName Emanuela
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210215667.35
279 rdf:type schema:Person
280 sg:person.01235471460.73 schema:affiliation grid-institutes:grid.419038.7
281 schema:familyName Paioli
282 schema:givenName Anna
283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235471460.73
284 rdf:type schema:Person
285 sg:person.01275354033.99 schema:affiliation grid-institutes:grid.412311.4
286 schema:familyName Nanni
287 schema:givenName Cristina
288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275354033.99
289 rdf:type schema:Person
290 sg:person.013005321532.44 schema:affiliation grid-institutes:grid.419038.7
291 schema:familyName Ferrari
292 schema:givenName Stefano
293 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013005321532.44
294 rdf:type schema:Person
295 sg:person.01334463454.00 schema:affiliation grid-institutes:grid.419038.7
296 schema:familyName Gambarotti
297 schema:givenName Marco
298 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334463454.00
299 rdf:type schema:Person
300 sg:person.0705203110.24 schema:affiliation grid-institutes:grid.419038.7
301 schema:familyName De Paolis
302 schema:givenName Massimiliano
303 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0705203110.24
304 rdf:type schema:Person
305 sg:person.0715016706.32 schema:affiliation grid-institutes:grid.412311.4
306 schema:familyName Fanti
307 schema:givenName Stefano
308 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0715016706.32
309 rdf:type schema:Person
310 sg:person.0720354404.13 schema:affiliation grid-institutes:grid.419038.7
311 schema:familyName Marchesi
312 schema:givenName Emanuela
313 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720354404.13
314 rdf:type schema:Person
315 sg:person.0753274552.44 schema:affiliation grid-institutes:grid.419038.7
316 schema:familyName Picci
317 schema:givenName Piero
318 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753274552.44
319 rdf:type schema:Person
320 sg:pub.10.1007/s00259-013-2344-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010594474
321 https://doi.org/10.1007/s00259-013-2344-8
322 rdf:type schema:CreativeWork
323 sg:pub.10.1007/s00259-015-3200-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013429857
324 https://doi.org/10.1007/s00259-015-3200-9
325 rdf:type schema:CreativeWork
326 sg:pub.10.1007/s002590000340 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019676038
327 https://doi.org/10.1007/s002590000340
328 rdf:type schema:CreativeWork
329 sg:pub.10.1007/s10549-014-2924-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049588764
330 https://doi.org/10.1007/s10549-014-2924-8
331 rdf:type schema:CreativeWork
332 sg:pub.10.1007/s12094-015-1351-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009995151
333 https://doi.org/10.1007/s12094-015-1351-6
334 rdf:type schema:CreativeWork
335 sg:pub.10.1186/1477-7819-12-26 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032219566
336 https://doi.org/10.1186/1477-7819-12-26
337 rdf:type schema:CreativeWork
338 grid-institutes:grid.412311.4 schema:alternateName Nuclear Medicine, Sant’ Orsola Hospital, Bologna, Italy
339 schema:name Nuclear Medicine, Sant’ Orsola Hospital, Bologna, Italy
340 rdf:type schema:Organization
341 grid-institutes:grid.419038.7 schema:alternateName Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
342 Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
343 Radiology, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
344 Research Laboratory, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
345 schema:name Chemotherapy, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
346 Orthopaedic Surgery, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
347 Radiology, Musculoskeletal Oncology Department, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
348 Research Laboratory, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
349 Surgical Pathology, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136, Bologna, Italy
350 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...